MycoSynVac – Engineering bacteria to design vaccines, is a EC funded project, combining gene engineering and biotechnology to design a veterinary vaccine chassis based on the living organism Mycoplasma.
- Researchers will put together their extensive systems biology knowledge and cutting-edge synthetic biology methodologies to engineer a universal chassis, which will be free of virulence and optimized for fast growth in a serum-free medium.
- The resulting chassis will be used to create specific vaccines against two pathogens that are causing suffering in livestock animals and large financial losses in the animal industry. It also will set the basis for other potential applications such as cell therapy, infectious lung disease treatment, etc.
- MycoSynVac is a 8 M€ H2020 EU project coordinated by scientists at the Centre for Genomic Regulation in Barcelona (Spain) and with participation of partners in The Netherlands, France, UK, Germany, Denmark and Austria (Biofaction).
Biofaction is responsible of dissemination and public engagement of the project.
MycoSynVac, that has been launched beginning of April 2015, is a 5 years project that received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634942.
- Centre for Genomic Regulation
- MSD Animal Health
- Wageningen University (WU)
- Imperial College (IC)
- University of Copenhagen (UCPH)
- Biofaction KG